New Dual Antibiotic Effective Against Changing Hospital Flora

Oncology NEWS InternationalOncology NEWS International Vol 4 No 10
Volume 4
Issue 10

MONTREAL-The newest beta-lactam plus beta-lactamase inhibitor combination, piperacillin/tazobactam (Zosyn), when combined with amikacin, is highly effective for empiric treatment of patients with febrile granulocyto-penia, Jean A. Klastersky, MD, said at the 19th International Congress of Chemotherapy. He was speaking at a symposium sponsored by Lederle/Wyeth-Ayerst International, manufacturer of Zosyn.

MONTREAL-The newest beta-lactam plus beta-lactamase inhibitorcombination, piperacillin/tazobactam (Zosyn), when combined withamikacin, is highly effective for empiric treatment of patientswith febrile granulocyto-penia, Jean A. Klastersky, MD, said atthe 19th International Congress of Chemotherapy. He was speakingat a symposium sponsored by Lederle/Wyeth-Ayerst International,manufacturer of Zosyn.

In a study conducted by the International Antimicrobial TherapyCooperative Group (IATCG) of the European Organization for Researchand Treatment of Cancer (EORTC), 61% of 342 febrile episodes weresuccessfully treated with the piperacillin/tazobactam-amikacincombination, compared with 54% of 364 episodes treated with cef-tazidimeplus amikacin (P = .05), Dr. Klastersky said.

Moreover, time to defervescence was significantly shorter (P= .01) and the time to failure was significantly longer
(P = .05) with the newer antibiotic regimen (AntimicrobialAgents and Chemotherapy 39:445-452, 1995).

Noting that standard antibiotic strategies devised a decade agowere directed primarily against gram-negative organisms, Dr. Klastersky,chief of medicine, Institut Jules Bordet, Brussels, Belgium, explainedthat today's hospital flora are drastically different. Althoughnot quite as lethal as some of the gram-negative strains suchas Pseudomonas aeruginosa, as many as 80% of infectionsin neutro-penic patients are now traced to gram-positive bacteria.

Vancomycin Resistance

To ensure adequate coverage for both gram-negative and gram-positiveorganisms, some experts have suggested combining ceftazidime withvancomycin. Dr. Klastersky noted that this strategy works, "butthere is a price to be paid in terms of the emergence of vancomycin-resistantmicrobes."

Stressing the importance of reserving vancomycin for treatmentof methicillin-resistant gram-positive bacteria, he characterizedvancomycin-containing combinations for empiric therapy as beingunnecessary in most cases.

Any new antibiotic regimen for empiric therapy of febrile neutropenicpatients should have improved activity against gram-positive organismswhile retaining potency against dangerous infections with gram-negatives,Dr. Klastersky said. One of the primary objectives of the IATCG-EORTCstudy was to assess the effectiveness of the piper-acillin/tazobactam-amikacincombination for treatment of infections due to gram-positive bacteria.

When the investigators analyzed microbiologically documented infections,they noted that 161 episodes of bactere-mia were due to singleorganisms, most frequently, to coagulase-negative staphylococciand viridans group streptococci. Patients' responses to bacteremicinfections differed according to the treatment they received:50% of those given piperacillin/tazobactam-amikacin were successfullytreated, compared with only 35% of those who received ceftazidime-amikacin(P = .05).

Dr. Klastersky reported that these results were confirmed in aseparate study conducted at eight medical centers in France. Inaddition to better control of fever, the combination of piperacillin/tazobactam-amikacinin the multicenter French study was also associated with a lowerincidence of superinfection
(P = .08), fewer days of fever during aplasia (P= .01), fewer antibiotic changes during the entire neutropenicperiod (P = .02), and a reduced need for van-comycin (P= .01).

Because these neutropenic patients are vulnerable to infection,especially if granulocytopenia is prolonged, the benefit of colony-stimulatingfactors as a complement to effective antibiotic regimens mustbe assessed in appropriate trials, he said, but to date thereis no clear indication that the use of these factors modifiesthe ultimate outcome.

Related Videos
More funding is necessary for additional trials investigating the potential clinical benefit of an alpha-lactalbumin vaccine for patients with high-risk operable triple-negative breast cancer and those at high risk of developing the disease, says G. Thomas Budd, MD.
Ghayas C. Issa, MD, an expert on acute myeloid leukemia
Ghayas C. Issa, MD, an expert on acute myeloid leukemia
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Related Content